ylliX - Online Advertising Network
Press Release

EU Backs Merck’s COVID-19 Pill For Adults At Risk Of Severe Illness

EU Backs Merck's COVID-19 Pill For Adults At Risk Of Severe Illness

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

EMA’s human medicines committee (CHMP) advised that the COVID-19 pill from Merck & Co Inc (NYSE: MRK) should be given within five days of first symptoms to treat adults who do not need oxygen support and are at risk of their disease worsening. The European Medicines Agency (EMA) said the pill, developed along with Ridgeback Biotherapeutics, should be taken twice a day for five days.

...read full article on Benzinga

ylliX - Online Advertising Network